PDGF BB induces VEGF secretion in ovarian cancer

Daniela Matei, Stephanie Kelich, Liyun Cao, Nancy Menning, Robert Emerson, Jyiannu Rao, Huey Jeng Meei, George W. Sledge

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

We identified the platelet derived growth factor receptor (PDGFR) as a potential target in epithelial ovarian carcinoma (EOC). This led us to test whether inhibition of the PDGFR affects ovarian cancer cell proliferation and survival and regulates other processes critical to tumor growth and metastasis. We postulated that there is a correlation between the PDGF-PDGFR axis and the secretion of VEGF in EOC. VEGF secretion in ovarian tumors, cancer cells, serum and ascites fluid was measured by IHC, Western Blot and ELISA. We found increased VEGF expression and secretion in most ovarian tumors (by IHC), in EOC malignant ascites and in the conditioned media of primary ovarian cancer cells (quantified by ELISA). In malignant ascites, the levels of secreted PDGF BB and VEGF were strongly correlated (Pearson coefficient of correlation R = 0.728), suggesting that the two pathways interconnect. In PDGFR expressing immortalized ovarian cancer cells, PDGF potently induced VEGF secretion, while imatinib mesylate (Gleevec), a partially selective PDGFR inhibitor, reduced PDGF stimulated VEGF production to basal state. In ovarian cancer cells overexpressing constitutively active Akt, imatinib inhibited partially VEGF secretion, suggesting that the PI3K/Akt pathway is implicated in PDGF-stimulated VEGF secretion. In summary, these results suggest a correlation between the PDGF and VEGF networks in ovarian cancer cells and tumors. The effects of imatinib on VEGF secretion in tumor cells may affect the tumor microenvironment in a manner detrimental to tumor progression.

Original languageEnglish
Pages (from-to)1951-1959
Number of pages9
JournalCancer Biology and Therapy
Volume6
Issue number12
StatePublished - Dec 2007

Fingerprint

Ovarian Neoplasms
Vascular Endothelial Growth Factor A
Platelet-Derived Growth Factor Receptors
Ascites
Neoplasms
Carcinoma
Enzyme-Linked Immunosorbent Assay
platelet-derived growth factor BB
Tumor Microenvironment
Conditioned Culture Medium
Phosphatidylinositol 3-Kinases
Cell Survival
Western Blotting
Cell Proliferation
Neoplasm Metastasis
Imatinib Mesylate
Growth
Serum

Keywords

  • Imatinib mesylate
  • Ovarian cancer
  • Platelet derived growth factor receptor
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Matei, D., Kelich, S., Cao, L., Menning, N., Emerson, R., Rao, J., ... Sledge, G. W. (2007). PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biology and Therapy, 6(12), 1951-1959.

PDGF BB induces VEGF secretion in ovarian cancer. / Matei, Daniela; Kelich, Stephanie; Cao, Liyun; Menning, Nancy; Emerson, Robert; Rao, Jyiannu; Meei, Huey Jeng; Sledge, George W.

In: Cancer Biology and Therapy, Vol. 6, No. 12, 12.2007, p. 1951-1959.

Research output: Contribution to journalArticle

Matei, D, Kelich, S, Cao, L, Menning, N, Emerson, R, Rao, J, Meei, HJ & Sledge, GW 2007, 'PDGF BB induces VEGF secretion in ovarian cancer', Cancer Biology and Therapy, vol. 6, no. 12, pp. 1951-1959.
Matei D, Kelich S, Cao L, Menning N, Emerson R, Rao J et al. PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biology and Therapy. 2007 Dec;6(12):1951-1959.
Matei, Daniela ; Kelich, Stephanie ; Cao, Liyun ; Menning, Nancy ; Emerson, Robert ; Rao, Jyiannu ; Meei, Huey Jeng ; Sledge, George W. / PDGF BB induces VEGF secretion in ovarian cancer. In: Cancer Biology and Therapy. 2007 ; Vol. 6, No. 12. pp. 1951-1959.
@article{2fa6824356d24b83b9fc81fff4b447b9,
title = "PDGF BB induces VEGF secretion in ovarian cancer",
abstract = "We identified the platelet derived growth factor receptor (PDGFR) as a potential target in epithelial ovarian carcinoma (EOC). This led us to test whether inhibition of the PDGFR affects ovarian cancer cell proliferation and survival and regulates other processes critical to tumor growth and metastasis. We postulated that there is a correlation between the PDGF-PDGFR axis and the secretion of VEGF in EOC. VEGF secretion in ovarian tumors, cancer cells, serum and ascites fluid was measured by IHC, Western Blot and ELISA. We found increased VEGF expression and secretion in most ovarian tumors (by IHC), in EOC malignant ascites and in the conditioned media of primary ovarian cancer cells (quantified by ELISA). In malignant ascites, the levels of secreted PDGF BB and VEGF were strongly correlated (Pearson coefficient of correlation R = 0.728), suggesting that the two pathways interconnect. In PDGFR expressing immortalized ovarian cancer cells, PDGF potently induced VEGF secretion, while imatinib mesylate (Gleevec), a partially selective PDGFR inhibitor, reduced PDGF stimulated VEGF production to basal state. In ovarian cancer cells overexpressing constitutively active Akt, imatinib inhibited partially VEGF secretion, suggesting that the PI3K/Akt pathway is implicated in PDGF-stimulated VEGF secretion. In summary, these results suggest a correlation between the PDGF and VEGF networks in ovarian cancer cells and tumors. The effects of imatinib on VEGF secretion in tumor cells may affect the tumor microenvironment in a manner detrimental to tumor progression.",
keywords = "Imatinib mesylate, Ovarian cancer, Platelet derived growth factor receptor, VEGF",
author = "Daniela Matei and Stephanie Kelich and Liyun Cao and Nancy Menning and Robert Emerson and Jyiannu Rao and Meei, {Huey Jeng} and Sledge, {George W.}",
year = "2007",
month = "12",
language = "English",
volume = "6",
pages = "1951--1959",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "12",

}

TY - JOUR

T1 - PDGF BB induces VEGF secretion in ovarian cancer

AU - Matei, Daniela

AU - Kelich, Stephanie

AU - Cao, Liyun

AU - Menning, Nancy

AU - Emerson, Robert

AU - Rao, Jyiannu

AU - Meei, Huey Jeng

AU - Sledge, George W.

PY - 2007/12

Y1 - 2007/12

N2 - We identified the platelet derived growth factor receptor (PDGFR) as a potential target in epithelial ovarian carcinoma (EOC). This led us to test whether inhibition of the PDGFR affects ovarian cancer cell proliferation and survival and regulates other processes critical to tumor growth and metastasis. We postulated that there is a correlation between the PDGF-PDGFR axis and the secretion of VEGF in EOC. VEGF secretion in ovarian tumors, cancer cells, serum and ascites fluid was measured by IHC, Western Blot and ELISA. We found increased VEGF expression and secretion in most ovarian tumors (by IHC), in EOC malignant ascites and in the conditioned media of primary ovarian cancer cells (quantified by ELISA). In malignant ascites, the levels of secreted PDGF BB and VEGF were strongly correlated (Pearson coefficient of correlation R = 0.728), suggesting that the two pathways interconnect. In PDGFR expressing immortalized ovarian cancer cells, PDGF potently induced VEGF secretion, while imatinib mesylate (Gleevec), a partially selective PDGFR inhibitor, reduced PDGF stimulated VEGF production to basal state. In ovarian cancer cells overexpressing constitutively active Akt, imatinib inhibited partially VEGF secretion, suggesting that the PI3K/Akt pathway is implicated in PDGF-stimulated VEGF secretion. In summary, these results suggest a correlation between the PDGF and VEGF networks in ovarian cancer cells and tumors. The effects of imatinib on VEGF secretion in tumor cells may affect the tumor microenvironment in a manner detrimental to tumor progression.

AB - We identified the platelet derived growth factor receptor (PDGFR) as a potential target in epithelial ovarian carcinoma (EOC). This led us to test whether inhibition of the PDGFR affects ovarian cancer cell proliferation and survival and regulates other processes critical to tumor growth and metastasis. We postulated that there is a correlation between the PDGF-PDGFR axis and the secretion of VEGF in EOC. VEGF secretion in ovarian tumors, cancer cells, serum and ascites fluid was measured by IHC, Western Blot and ELISA. We found increased VEGF expression and secretion in most ovarian tumors (by IHC), in EOC malignant ascites and in the conditioned media of primary ovarian cancer cells (quantified by ELISA). In malignant ascites, the levels of secreted PDGF BB and VEGF were strongly correlated (Pearson coefficient of correlation R = 0.728), suggesting that the two pathways interconnect. In PDGFR expressing immortalized ovarian cancer cells, PDGF potently induced VEGF secretion, while imatinib mesylate (Gleevec), a partially selective PDGFR inhibitor, reduced PDGF stimulated VEGF production to basal state. In ovarian cancer cells overexpressing constitutively active Akt, imatinib inhibited partially VEGF secretion, suggesting that the PI3K/Akt pathway is implicated in PDGF-stimulated VEGF secretion. In summary, these results suggest a correlation between the PDGF and VEGF networks in ovarian cancer cells and tumors. The effects of imatinib on VEGF secretion in tumor cells may affect the tumor microenvironment in a manner detrimental to tumor progression.

KW - Imatinib mesylate

KW - Ovarian cancer

KW - Platelet derived growth factor receptor

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=42549156263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42549156263&partnerID=8YFLogxK

M3 - Article

C2 - 18075302

AN - SCOPUS:42549156263

VL - 6

SP - 1951

EP - 1959

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 12

ER -